Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels
- PMID: 19670414
- DOI: 10.1002/hep.23135
Ultrasonographic hepatic steatosis increases prediction of mortality risk from elevated serum gamma-glutamyl transpeptidase levels
Abstract
The aim of the present study was to investigate the association of serum gamma-glutamyltransferase (GGT) levels with all-cause mortality and to assess the impact of ultrasonographic findings of hepatic hyperechogenicity in that association. We used data from 4,160 subjects (2,044 men and 2,116 women) recruited for the population-based Study of Health in Pomerania (SHIP) without baseline hepatitis B and C infections or liver cirrhosis. GGT was divided into age- and sex-dependent quintiles to calculate overall and sex-specific crude incidence mortality rates. Hepatic steatosis was defined by elevated GGT levels (>80%) and the presence of hyperechogenic liver ultrasound. We used multiple-adjusted Cox proportional hazards regression models, first, to assess the direct effect of GGT on all-cause mortality, second, to stratify according to the ultrasonographic finding, and third, to investigate potential mediating effects of cardiometabolic risk factors. During 29,810 person-years (7.3 years, median) of follow-up, 307 individuals (7.5%) died, resulting in a death rate of 0.86 deaths per 1000 person-years. Elevated GGT levels were associated with increased risk of mortality in men (hazard ratio [HR] 1.49; 95% confidence interval [CI], 1.08-2.05), but not in women (HR 1.30; 95% CI, 0.80-2.12). This association was even stronger in men with hepatic steatosis (HR 1.98; 95% CI, 1.21-3.27). Cause-specific mortality analysis by cardiovascular disease deaths confirmed the sex-specific association. Adjustment for cardiometabolic risk factors did not affect the estimates.
Conclusion: In the case of increased GGT levels, liver ultrasound should be performed, not only for diagnosis, but also for further risk stratification.
Comment in
-
From liver markers to life expectancy.Hepatology. 2010 Feb;51(2):720; author reply 720-1. doi: 10.1002/hep.23452. Hepatology. 2010. PMID: 20101756 No abstract available.
Similar articles
-
Association between hepatic steatosis and serum liver enzyme levels with atrial fibrillation in the general population: The Study of Health in Pomerania (SHIP).Atherosclerosis. 2016 Feb;245:123-31. doi: 10.1016/j.atherosclerosis.2015.12.023. Epub 2015 Dec 18. Atherosclerosis. 2016. PMID: 26722832
-
Serum γ-glutamyltransferase: independent predictor of risk of diabetes, hypertension, metabolic syndrome, and coronary disease.Obesity (Silver Spring). 2012 Apr;20(4):842-8. doi: 10.1038/oby.2011.136. Epub 2011 Jun 2. Obesity (Silver Spring). 2012. PMID: 21633402
-
Elevated serum alanine aminotransferase and gamma-glutamyltransferase and mortality in the United States population.Gastroenterology. 2009 Feb;136(2):477-85.e11. doi: 10.1053/j.gastro.2008.10.052. Epub 2008 Oct 29. Gastroenterology. 2009. PMID: 19100265
-
Liver enzymes, nonalcoholic fatty liver disease, and incident cardiovascular disease: a narrative review and clinical perspective of prospective data.Hepatology. 2010 Sep;52(3):1156-61. doi: 10.1002/hep.23789. Hepatology. 2010. PMID: 20658466 Review.
-
Association of serum gamma-glutamyltransferase with chronic kidney disease risk: a meta-analysis.Free Radic Res. 2018 Aug;52(8):819-825. doi: 10.1080/10715762.2018.1492120. Free Radic Res. 2018. PMID: 30208797 Review.
Cited by
-
Dietary characteristics associated with the risk of non-alcoholic fatty liver disease and metabolic dysfunction-associated steatotic liver disease in non-obese Japanese participants: A cross-sectional study.JGH Open. 2024 May 22;8(5):e13082. doi: 10.1002/jgh3.13082. eCollection 2024 May. JGH Open. 2024. PMID: 38779132 Free PMC article.
-
Bridging Metabolic-Associated Steatotic Liver Disease and Cardiovascular Risk: A Potential Role for Ketogenesis.Biomedicines. 2024 Mar 20;12(3):692. doi: 10.3390/biomedicines12030692. Biomedicines. 2024. PMID: 38540305 Free PMC article. Review.
-
The therapeutic mechanisms and beneficial effects of ursodeoxycholic acid in the treatment of nonalcoholic fatty liver disease: a systematic review.Med Pharm Rep. 2024 Jan;97(1):12-25. doi: 10.15386/mpr-2629. Epub 2024 Jan 29. Med Pharm Rep. 2024. PMID: 38344336 Free PMC article. Review.
-
The Independent Association of Non-alcoholic Fatty Liver Disease With Incident Cardiovascular Disease: A GRADE Evaluation of the Evidence Through a Systematic Review and Meta-analysis.J Clin Exp Hepatol. 2024 Jan-Feb;14(1):101277. doi: 10.1016/j.jceh.2023.08.013. Epub 2023 Sep 9. J Clin Exp Hepatol. 2024. PMID: 38076375
-
Long-term exposure to air pollution and prevalent nonalcoholic fatty liver disease.Environ Epidemiol. 2023 Aug 31;7(5):e268. doi: 10.1097/EE9.0000000000000268. eCollection 2023 Oct. Environ Epidemiol. 2023. PMID: 37840860 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Miscellaneous